HEK293-CTLA4 Cells

Unit

3 x 10^6 cells/ml

Cell Type

Stable (KO/Expressing) Cells

Tissue Type

Transformed cell lines

Organism

Human

Donor History

Transformed/immortalized; non-tumorigenic (HEK293 background)

Growth Properties

Monolayer

,

adherent

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS

,

1 mM sodium pyruvate

,

10 mM HEPES

,

1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. Dissociation reagent: Trypsin-EDTA. Seeding density: 2 to 4 x 10⁴ cells/cm². Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/HEK293-CTLA4-Cells/305423

Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. If you represent a commercial entity or are unsure which category applies, please
contact us.
The HEK293-CTLA4 cell line is a stable recombinant HEK293 cell line engineered to express the CTLA4 receptor at a medium-low level, approximately 4,000 molecules per cell. This cell line was developed using inscreenex’s landing pad technology, ensuring precise and reproducible integration of the CTLA4 gene at a specific, pre-validated genomic locus. CTLA4, also known as CD152, is an immune checkpoint protein that plays a crucial role in regulating T-cell activation. By competing with the stimulatory receptor CD28 for binding to B7 molecules (CD80 and CD86) on antigen-presenting cells, CTLA4 downregulates immune responses, thus maintaining self-tolerance and preventing autoimmunity. CTLA4 is a key target in cancer immunotherapy, particularly for drugs like ipilimumab, which aim to enhance anti-tumor immunity by blocking this checkpoint and activating T cells.The expression of CTLA4 in this cell line was confirmed using flow cytometry with a target-specific antibody, ensuring reliable and consistent receptor density across the cell population.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.